We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Single-Tube Multimarker Assay Estimates Preeclampsia Risk

By LabMedica International staff writers
Posted on 03 Dec 2020
The challenge in the clinical practice of pregnancy monitoring is to distinguish isolated gestational hypertension or proteinuria from the development of preeclampsia (PE) with potential severe consequences to the mother and unborn child.

PE is considered a disease of placenta, caused by defective placental formation and/or its impaired functional capacity. More...
The molecules secreted by placenta and released to the maternal blood stream have been the most popular candidates of noninvasive biomarkers for PE prognosis.

Biomedical Scientists at the University of Tartu (Tartu, Estonia) recruited both pregnant women and a subgroup of healthy non-pregnant women. The study included 53 spontaneously conceived single pregnancy cases representing alternative gestational curricula with respect to the development of PE. During the index pregnancy, 22 women had eventually developed PE (age 28.0 ± 5.2 years; nulliparity 77%; male newborn 54.5%) and 31 gestations proceeded until delivery without PE (aged 28.5 ± 5.1 years; nulliparity 51.6%; male newborn 48.4%).

The team developed and used the Luminex xMAP based assay (Luminex Corporation, Austin TX, USA) that was targeted to previously established maternal serum biomarkers for PE prediction: Soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), soluble endoglin (sENG), leptin, disintegrin and metalloproteinase domain-containing protein 12 (ADAM12), adiponectin, and Pentraxin 3 (PTX3). The B•R•A•H•M•S Kryptor sFlt-1/PlGF test (Thermo Fisher Scientific, Hennigsdorf, Germany) was applied as an external reference. Alternative PE prediction formulae combining 6PLEX measurements with clinical parameters were developed.

The scientists reported there was a high correlation in sFlt-1/PlGF estimated for individual sera between the 6PLEX and B·R·A·H·M·S Kryptor immunoassays. The predictive power of the 6PLEX combined with gestational age and maternal weight at sampling reached AUC 0.99 with sensitivity 100.0% and specificity 96.9%. In all models, sFlt-1/PlGF derived from the B·R·A·H·M·S immunoassays exhibited the lowest AUC value (<0.87) and sensitivity (<80%) with broad confidence intervals (13%–92%). The estimated prognostic yield of the 6PLEX compared to the B·R·A·H·M·S assay was significantly higher (96.5% versus 73.7%).

The authors concluded that the developed single-tube multimarker assay for PE risk estimation in combination with clinical symptoms reached high prognostic yield (96.5%) and exhibited superior performance compared to the sFlt-1/PlGF test. The study was published in the November, 2020 issue of The Journal of Applied Laboratory Medicine.





New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Increased polysialic acid in schizophrenia patients represents a potential diagnostic tool and possible target for treatment (Photo courtesy of 123RF)

New Technique for Measuring Acidic Glycan in Blood Simplifies Schizophrenia Diagnosis

Polysialic acid is a unique acidic glycan predominantly found in brain regions associated with memory and emotion, but it is also present in the bloodstream. Research has shown that blood levels of polysialic... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.